ArticleJournal of ophthalmic & vision research2009
Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders.
Article in Journal of ophthalmic & vision research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A Systematic Review of Tear Vascular Endothelial Growth Factor and External Eye Diseases.International journal of molecular sciences · 2024Pooled it
- Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.The British journal of ophthalmology · 2022Trial
- Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Review
- Utilization of Nanoparticles for Treating Age-Related Macular Degeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits.Molecular pharmaceutics · 2024Article
- Review
- Thymoquinone in Ocular Neurodegeneration: Modulation of Pathological Mechanisms via Multiple Pathways.Frontiers in cellular neuroscience · 2022Review
- Disease progression pathways of wet AMD: opportunities for new target discovery.Expert opinion on therapeutic targets · 2022Review
- Short-Term Combined Exercise Improves Inflammatory Profile in the Retina of Obese Mice.International journal of molecular sciences · 2020Article
- CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.Progress in retinal and eye research · 2018Review
- Article
- Introduction. Treatment paradigms within the use of anti-VEGF agents.The British journal of ophthalmology · 2014Article
- Screening of antiangiogenic potential of twenty two marine invertebrate extracts of phylum Mollusca from South East Coast of India.Asian Pacific journal of tropical biomedicine · 2014Article
- Effect of Faricimab on Visual Acuity and Retinal Structure in Neovascular Age-Related Macular Degeneration Previously Treated With Anti-VEGF Therapy.Journal of vitreoretinal diseasesArticle
- Corneal Endothelial Cell Changes Associated with Multiple Intravitreal Injections.Journal of current ophthalmologyArticle
- A Long-term Clinical Study to Evaluate AGV with Concurrent Intravitreal Ranibizumab vs Primary AGV Implantation in Cases of Refractory Neovascular Glaucoma.Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of pharmacotherapy has been one of the most important advances in the management of retinal disorders. Age-related macular degeneration (AMD) was once considered as an irrepressible disease leading to permanent macular damage, however anti-vascular endothelial growth factor (anti-VEGF) agents are now believed to halt the progression of the condition and improve vision in a considerable proportion of patients. Anti-VEGF agents are among the most commonly used drugs in ophthalmology but questions and uncertainties still surround their indications, efficacy and complications. This paper reviews the role of VEGF under physiologic and pathologic conditions in the eye and available anti-VEGF agents in current ophthalmic practice.
Indexed as
Identifiers
23198057PMC3498546W198864342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.